We have opened a Boyds US office in King of Prussia on the outskirts of Philadelphia.
The opening of the office follows last year’s announcement of Boyds’ launch into the US along with the appointment of Katy Rudnick as Vice President and Head of US Regulatory Affairs.
Since Boyds was established in 2005, the company has worked with US companies seeking to develop and gain approval for their medicines in Europe and further afield. Boyds’ global reputation for its work in advanced therapies has led to a steady increase in the number of companies approaching Boyds for this expertise, with over 60% of the company’s client base now in the US.
The office is ideally located for many of Boyds’ East Coast clients and provides the opportunity for further growth and expansion in the US.
President and Founder Professor Alan Boyd, says: “The US is the largest biotech market globally, and is of strategic importance to our growth. US companies continue to turn to us for our expertise in supporting the development of cutting-edge and advanced therapies. The office in the King of Prussia region is the next step for us in our commitment to working closely with US clients looking to develop and take their products forward for approval with regulators in the US, but also the UK and Europe, via our UK and Dublin offices.”
Boyds US:
630 Freedom Business Center, Third Floor, King of Prussia, PA 19406, USA
T +1 800 982 7431
